DK2673262T3 - Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser - Google Patents

Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser Download PDF

Info

Publication number: DK2673262T3
Authority: DK; Denmark
Prior art keywords: compounds; processes; preparation; pharmaceutical compositions; compositions containing
Prior art date: 2011-02-10

Application number

DK12704492.3T

Other languages

English (en)

Inventor

Jo Ann Wilson

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-10

Filing date

2012-02-10

Publication date

2022-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45615082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2673262(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-02-10 Application filed by Exelixis Inc filed Critical Exelixis Inc

2022-01-24 Application granted granted Critical

2022-01-24 Publication of DK2673262T3 publication Critical patent/DK2673262T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

DK12704492.3T 2011-02-10 2012-02-10 Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser DK2673262T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161441520P	2011-02-10	2011-02-10
US201161441527P	2011-02-10	2011-02-10
PCT/US2012/024591 WO2012109510A1 (en)	2011-02-10	2012-02-10	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds

Publications (1)

Publication Number	Publication Date
DK2673262T3 true DK2673262T3 (da)	2022-01-24

Family

ID=45615082

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12704492.3T DK2673262T3 (da)	2011-02-10	2012-02-10	Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser

Country Status (21)

Country	Link
US (11)	US9717720B2 (da)
EP (2)	EP2673262B1 (da)
JP (2)	JP2014505109A (da)
KR (7)	KR20210147117A (da)
CN (1)	CN103459373B (da)
AR (1)	AR085155A1 (da)
AU (6)	AU2012214322B2 (da)
BR (1)	BR112013020362A2 (da)
CA (1)	CA2826751C (da)
DK (1)	DK2673262T3 (da)
EA (1)	EA033513B1 (da)
ES (1)	ES2905571T3 (da)
GE (3)	GEP20217235B (da)
HU (1)	HUE057574T2 (da)
IL (1)	IL227848B (da)
MX (2)	MX390726B (da)
PL (1)	PL2673262T3 (da)
PT (1)	PT2673262T (da)
TW (2)	TWI640509B (da)
WO (1)	WO2012109510A1 (da)
ZA (1)	ZA201306072B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA038195B1 (ru)	2009-01-16	2021-07-22	Экселиксис, Инк.	Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
WO2012009722A1 (en)	2010-07-16	2012-01-19	Exelixis, Inc.	C-met modulator pharmaceutical compositions
DK2621481T4 (da)	2010-09-27	2023-01-09	Exelixis Inc	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI640509B (zh)	2011-02-10	2018-11-11	艾克塞里克斯公司	製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
TWI610918B (zh)	2011-05-02	2018-01-11	艾克塞里克斯公司	治療癌症及骨癌疼痛之方法
GEP201606523B (en)	2011-09-22	2016-08-10	Exelixis Inc	Method for treating osteoporosis
EP2768796B1 (en)	2011-10-20	2019-11-20	Exelixis, Inc.	Process for preparing quinoline derivatives
WO2013166296A1 (en)	2012-05-02	2013-11-07	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) *	2012-09-26	2016-05-04	正大天晴药业集团股份有限公司	一种酪氨酸激酶抑制剂及其中间体的制备方法
CA2907334C (en)	2013-03-15	2021-12-07	Exelixis, Inc.	Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en)	2013-04-04	2023-01-31	Exelixis, Inc.	Cabozantinib dosage form and use in the treatment of cancer
CN103751140A (zh) *	2014-01-15	2014-04-30	青岛市肿瘤医院	一种Cabozantinib分散片及其制备方法
AU2015218236B2 (en)	2014-02-14	2019-06-13	Exelixis, Inc.	Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
US10159666B2 (en)	2014-03-17	2018-12-25	Exelixis, Inc.	Dosing of cabozantinib formulations
CN104788372B (zh) *	2014-07-25	2018-01-30	上海圣考医药科技有限公司	一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh)	2014-07-31	2021-07-23	埃克塞里艾克西斯公司	制备氟-18标记的卡博替尼及其类似物的方法
BR112017002318A2 (pt)	2014-08-05	2018-07-17	Exelixis, Inc.	combinações de fármacos para tratar mieloma múltiplo.
CN105503717A (zh) *	2014-09-24	2016-04-20	江苏奥赛康药业股份有限公司	一种苹果酸卡博替尼化合物及其药物组合物
CN109069499A (zh)	2016-04-15	2018-12-21	埃克塞里艾克西斯公司	使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
JP2019529476A (ja)	2016-09-27	2019-10-17	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
IL270780B2 (en) *	2017-05-26	2025-04-01	Exelixis Inc	Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use
GEAP202415420A (en)	2018-01-26	2024-12-25	Exelixis Inc	Compounds for the treatment of kinase-dependent disorders
CN120305263A (zh)	2018-06-15	2025-07-15	汉达癌症医药责任有限公司	卡博替尼的盐类于制备治疗癌症的剂型的用途
CA3126721A1 (en)	2019-01-25	2020-07-30	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
EP4622961A1 (en)	2022-11-25	2025-10-01	Synthon B.V.	A process for preparation of cabozantinib or tivozanib
AU2024215796A1 (en)	2023-01-31	2025-05-15	Handa Oncology, Llc	Improved cabozantinib compositions and methods of use
CN116333534B (zh) *	2023-04-04	2023-11-17	清远拜克家居有限公司	一种耐老化木质板材用水性涂料及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
DE69733752T2 (de)	1996-05-20	2006-06-01	G.D. Searle Llc, Chicago	Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
CA2361057C (en) *	1999-01-22	2010-04-06	Kazuo Kubo	Quinoline derivatives and quinazoline derivatives
WO2003074497A1 (en)	2002-03-01	2003-09-12	Pintex Pharmaceutical, Inc.	Pin1-modulating compounds and methods of use thereof
JP3763414B2 (ja)	2002-10-21	2006-04-05	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
CA2744997A1 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and method of use
TWI347940B (en)	2003-11-07	2011-09-01	Novartis Ag	Methods for synthesizing quinolinone compounds
KR100839554B1 (ko)	2003-12-25	2008-06-20	에자이 알앤드디 매니지먼트 가부시키가이샤	4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의결정 및 이들의 제조 방법
WO2006014325A2 (en)	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
JP2008537748A (ja)	2005-04-06	2008-09-25	エクセリクシス、インコーポレイテッド	ｃ−Ｍｅｔモジュレーター及び使用方法
TWI392681B (zh)	2006-04-06	2013-04-11	Daiichi Sankyo Co Ltd	高純度普拉格雷及其酸加成鹽之製法
US20080004273A1 (en)	2006-05-30	2008-01-03	Stephane Raeppel	Inhibitors of protein tyrosine kinase activity
ES2703723T3 (es)	2006-12-14	2019-03-12	Exelixis Inc	Métodos para usar inhibidores de MEK
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) *	2008-05-08	2009-11-12	Takeda Pharmaceutical Company Limited	Fused heterocyclic derivatives and use thereof
AR075084A1 (es)	2008-09-26	2011-03-09	Smithkline Beecham Corp	Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CA2743416A1 (en)	2008-11-13	2010-05-20	Exelixis Inc.	Methods of preparing quinoline derivatives
EP2367795A1 (en)	2008-12-04	2011-09-28	Exelixis, Inc.	Methods of preparing quinoline derivatives
EA038195B1 (ru) *	2009-01-16	2021-07-22	Экселиксис, Инк.	Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
WO2010113183A2 (en)	2009-04-03	2010-10-07	Msn Laboratories Limited	Process for the preparation of 1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl] pyrrolidine and its pharmaceutically acceptable salts
EP2454238A1 (en)	2009-07-17	2012-05-23	Exelixis, Inc.	Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2475390A4 (en)	2009-09-09	2014-01-01	Quintiles Transnat Corp	METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
EP2545038A1 (en)	2010-03-12	2013-01-16	Exelixis, Inc.	Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en)	2010-04-16	2012-03-22	Exelixis, Inc.	Methods of Using C-Met Modulators
US20140186407A9 (en)	2010-07-16	2014-07-03	Exelixis Inc.	C-Met Modulator Pharmaceutical Compositions
WO2012009722A1 (en)	2010-07-16	2012-01-19	Exelixis, Inc.	C-met modulator pharmaceutical compositions
JP2013540759A (ja)	2010-09-27	2013-11-07	エクセリクシス，インク．	去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
DK2621481T4 (da)	2010-09-27	2023-01-09	Exelixis Inc	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
CN103391773A (zh)	2010-09-27	2013-11-13	埃克塞里艾克西斯公司	用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
JP2013543011A (ja)	2010-11-22	2013-11-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド	癌の治療法
TWI640509B (zh)	2011-02-10	2018-11-11	艾克塞里克斯公司	製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
TWI610918B (zh)	2011-05-02	2018-01-11	艾克塞里克斯公司	治療癌症及骨癌疼痛之方法
TW201306842A (zh)	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
GEP201606523B (en)	2011-09-22	2016-08-10	Exelixis Inc	Method for treating osteoporosis
EP2768796B1 (en)	2011-10-20	2019-11-20	Exelixis, Inc.	Process for preparing quinoline derivatives
EP2776033A1 (en)	2011-11-08	2014-09-17	Exelixis, Inc.	Dual inhibitor of met and vegf for treating cancer
WO2013166296A1 (en)	2012-05-02	2013-11-07	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
EP2892532B1 (en)	2012-09-07	2019-02-13	Exelixis, Inc.	Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
US20140221372A1 (en)	2013-02-06	2014-08-07	GlaxoSmithKline Intellectual Property (NO 2.) Limited	Method of administration and treatment
CA2907334C (en)	2013-03-15	2021-12-07	Exelixis, Inc.	Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
KR20150138268A (ko)	2013-04-04	2015-12-09	엑셀리시스, 인코포레이티드	암을 치료하기 위한 약물 병용요법
US10159666B2 (en)	2014-03-17	2018-12-25	Exelixis, Inc.	Dosing of cabozantinib formulations
AU2018279834B2 (en) *	2017-06-09	2024-05-23	Exelixis, Inc.	Liquid dosage forms to treat cancer

2012
- 2012-02-10 TW TW105117666A patent/TWI640509B/zh active
- 2012-02-10 DK DK12704492.3T patent/DK2673262T3/da active
- 2012-02-10 HU HUE12704492A patent/HUE057574T2/hu unknown
- 2012-02-10 MX MX2017012701A patent/MX390726B/es unknown
- 2012-02-10 GE GEAP201213221A patent/GEP20217235B/en unknown
- 2012-02-10 KR KR1020217038913A patent/KR20210147117A/ko not_active Ceased
- 2012-02-10 JP JP2013553580A patent/JP2014505109A/ja active Pending
- 2012-02-10 KR KR1020217002055A patent/KR20210010671A/ko not_active Ceased
- 2012-02-10 KR KR1020137023174A patent/KR102030447B1/ko active Active
- 2012-02-10 AU AU2012214322A patent/AU2012214322B2/en active Active
- 2012-02-10 WO PCT/US2012/024591 patent/WO2012109510A1/en not_active Ceased
- 2012-02-10 GE GEAP202413811A patent/GEAP202413811A/en unknown
- 2012-02-10 MX MX2013009116A patent/MX2013009116A/es unknown
- 2012-02-10 CA CA2826751A patent/CA2826751C/en active Active
- 2012-02-10 BR BR112013020362A patent/BR112013020362A2/pt not_active Application Discontinuation
- 2012-02-10 EP EP12704492.3A patent/EP2673262B1/en not_active Revoked
- 2012-02-10 KR KR1020247039112A patent/KR20240170977A/ko active Pending
- 2012-02-10 PT PT127044923T patent/PT2673262T/pt unknown
- 2012-02-10 CN CN201280017723.1A patent/CN103459373B/zh active Active
- 2012-02-10 KR KR1020237038819A patent/KR20230158644A/ko not_active Ceased
- 2012-02-10 US US13/984,559 patent/US9717720B2/en active Active
- 2012-02-10 EA EA201391145A patent/EA033513B1/ru not_active IP Right Cessation
- 2012-02-10 PL PL12704492T patent/PL2673262T3/pl unknown
- 2012-02-10 TW TW101104440A patent/TW201309650A/zh unknown
- 2012-02-10 ES ES12704492T patent/ES2905571T3/es active Active
- 2012-02-10 KR KR1020207007647A patent/KR20200031711A/ko not_active Ceased
- 2012-02-10 KR KR1020197012256A patent/KR20190049907A/ko not_active Ceased
- 2012-02-10 GE GEAP201213811A patent/GEP20247677B/en unknown
- 2012-02-10 EP EP21205831.7A patent/EP4019498A1/en active Pending
- 2012-02-10 AR ARP120100446A patent/AR085155A1/es not_active Application Discontinuation
2013
- 2013-08-07 IL IL227848A patent/IL227848B/en active IP Right Grant
- 2013-08-13 ZA ZA2013/06072A patent/ZA201306072B/en unknown
2016
- 2016-05-10 JP JP2016094411A patent/JP6513598B2/ja active Active
- 2016-11-10 US US15/348,716 patent/US10123999B2/en active Active
2017
- 2017-07-14 AU AU2017204877A patent/AU2017204877A1/en not_active Abandoned
2018
- 2018-10-04 US US16/151,653 patent/US10543206B2/en active Active
2019
- 2019-05-29 AU AU2019203745A patent/AU2019203745B2/en active Active
- 2019-12-06 US US16/706,323 patent/US20200108059A1/en not_active Abandoned
2020
- 2020-11-19 AU AU2020273307A patent/AU2020273307A1/en not_active Abandoned
2021
- 2021-01-19 US US17/152,394 patent/US20210154185A1/en not_active Abandoned
- 2021-02-08 US US17/170,275 patent/US11298349B2/en active Active
- 2021-10-08 US US17/497,201 patent/US20220023284A1/en not_active Abandoned
2022
- 2022-02-24 US US17/679,634 patent/US20220175757A1/en not_active Abandoned
- 2022-10-06 AU AU2022246429A patent/AU2022246429A1/en not_active Abandoned
2024
- 2024-02-08 US US18/436,836 patent/US12128039B2/en active Active
- 2024-07-31 AU AU2024205231A patent/AU2024205231A1/en active Pending
- 2024-09-27 US US18/899,774 patent/US20250017916A1/en not_active Abandoned
2025
- 2025-05-08 US US19/202,778 patent/US20250262200A1/en active Pending

Also Published As

Publication number	Publication date
EA033513B1 (ru)	2019-10-31
US11298349B2 (en)	2022-04-12
US20190030021A1 (en)	2019-01-31
US20210161885A1 (en)	2021-06-03
US20220175757A1 (en)	2022-06-09
BR112013020362A2 (pt)	2018-05-29
TW201706249A (zh)	2017-02-16
US10543206B2 (en)	2020-01-28
AU2022246429A1 (en)	2022-11-03
IL227848A0 (en)	2013-09-30
US12128039B2 (en)	2024-10-29
ZA201306072B (en)	2014-04-30
AU2017204877A1 (en)	2017-08-03
US20200108059A1 (en)	2020-04-09
KR20210010671A (ko)	2021-01-27
JP2014505109A (ja)	2014-02-27
EA201391145A1 (ru)	2014-09-30
IL227848B (en)	2020-09-30
CN103459373A (zh)	2013-12-18
KR20140044782A (ko)	2014-04-15
CA2826751A1 (en)	2012-08-16
TW201309650A (zh)	2013-03-01
TWI640509B (zh)	2018-11-11
AU2019203745A1 (en)	2019-06-20
US20210154185A1 (en)	2021-05-27
PT2673262T (pt)	2022-01-27
KR20210147117A (ko)	2021-12-06
AU2024205231A1 (en)	2024-08-22
US20250017916A1 (en)	2025-01-16
MX390726B (es)	2025-03-19
EP4019498A1 (en)	2022-06-29
AU2012214322A1 (en)	2013-08-29
KR20200031711A (ko)	2020-03-24
KR102030447B1 (ko)	2019-11-08
JP2016188216A (ja)	2016-11-04
KR20240170977A (ko)	2024-12-05
JP6513598B2 (ja)	2019-05-15
EP2673262B1 (en)	2021-11-03
EP2673262A1 (en)	2013-12-18
KR102030447B9 (ko)	2023-07-24
US20170057921A1 (en)	2017-03-02
HUE057574T2 (hu)	2022-05-28
PL2673262T3 (pl)	2022-04-11
WO2012109510A1 (en)	2012-08-16
MX2013009116A (es)	2014-01-31
US20220023284A1 (en)	2022-01-27
AU2012214322B2 (en)	2017-04-27
US20250262200A1 (en)	2025-08-21
GEP20217235B (en)	2021-03-25
US10123999B2 (en)	2018-11-13
US20140200242A1 (en)	2014-07-17
GEP20247677B (en)	2024-10-10
AU2019203745B2 (en)	2020-09-03
KR20190049907A (ko)	2019-05-09
AU2020273307A1 (en)	2020-12-17
ES2905571T3 (es)	2022-04-11
GEAP202413811A (en)	2024-06-29
NZ614130A (en)	2015-10-30
KR20230158644A (ko)	2023-11-20
US20240189298A1 (en)	2024-06-13
US9717720B2 (en)	2017-08-01
AR085155A1 (es)	2013-09-11
NZ712808A (en)	2017-03-31
CN103459373B (zh)	2018-02-23
CA2826751C (en)	2021-05-18

Publication	Publication Date	Title
DK3378862T3 (da)	2022-04-11	Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
IL227848B (en)	2020-09-30	Processes for preparing quinoline compounds and pharmaceutical preparations containing such compounds
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2804587T3 (da)	2019-08-12	Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2768796T3 (da)	2020-02-24	Fremgangsmåde til fremstilling af quinolin-derivater
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2445482T3 (da)	2014-09-22	Fremgangsmåde til fremstilling af beriget IgG sammensætning af plasma
DK3238709T3 (da)	2020-09-28	Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2898061T3 (da)	2020-02-10	Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
PL3156056T3 (pl)	2024-04-29	Kompozycje farmaceutyczne zawierające estry sorbitanu
DK2914248T4 (da)	2024-01-02	Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
DK3444342T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2558133T3 (da)	2020-04-06	Coatinger til fremstillingen og anvendelse af polyhydroxyalkanoat-lægemiddelindretninger
DK2917358T3 (da)	2019-09-30	Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
DK3290415T3 (da)	2021-03-22	Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme
LT3222272T (lt)	2021-12-27	Farmacinė karbetocino kompozicija
DK2704703T3 (da)	2019-10-14	Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK4082530T3 (da)	2024-05-06	Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2533761T3 (da)	2019-06-24	Fremgangsmåder og sammensætninger til fremstilling af aerosoler
DK3766522T3 (da)	2022-06-13	Automatiseret fremgangsmåde til fremstillingen af 18f-fluciclovin-sammensætninger
DK2635282T3 (da)	2022-10-17	Sammensætninger til behandling af myelofibrose
DK2627656T3 (da)	2014-09-08	Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
HUE036400T2 (hu)	2018-07-30	Omeprazol gyógyszerkészítmény
DK2939665T3 (da)	2019-06-11	Farmaceutisk sammensætning til behandling af hiv-infektioner
DK3524260T3 (da)	2023-10-09	Farmaceutiske sammensætninger til behandling af manglende appetit